| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6020358 | AMGEN INC | Substituted phenethylsulfones and method of reducing TNFα levels |
Oct, 2018
(5 years ago) | |
| US7893101 | AMGEN INC | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
Dec, 2023
(4 months ago) | |
| US7427638 | AMGEN INC | (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof |
Feb, 2028
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7208516 | AMGEN INC | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
Mar, 2023
(1 year, 1 month ago) | |
| US8802717 | AMGEN INC | Methods of treating arthritic conditions using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione |
Mar, 2023
(1 year, 1 month ago) | |
| US7659302 | AMGEN INC | Methods of using (+)-2-[1-(3-ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione |
Mar, 2023
(1 year, 1 month ago) | |
| US8455536 | AMGEN INC | Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione |
Mar, 2023
(1 year, 1 month ago) | |
| US6962940 | AMGEN INC | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
Mar, 2023
(1 year, 1 month ago) | |
| US9724330 | AMGEN INC | Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
Mar, 2023
(1 year, 1 month ago) | |
| US9018243 | AMGEN INC | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
Mar, 2023
(1 year, 1 month ago) | |
| US10092541 | AMGEN INC | Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast |
May, 2034
(10 years from now) | |
| US9872854 | AMGEN INC | Methods for the treatment of psoriatic arthritis using apremilast |
May, 2034
(10 years from now) | |
Otezla is owned by Amgen Inc.
Otezla contains Apremilast.
Otezla has a total of 12 drug patents out of which 9 drug patents have expired.
Expired drug patents of Otezla are:
- US7208516
- US8802717
- US7659302
- US8455536
- US6962940
- US9724330
- US9018243
- US6020358
- US7893101
Otezla was authorised for market use on 21 March, 2014.
Otezla is available in tablet;oral dosage forms.
Otezla can be used as use of otezla (apremilast) for inhibiting pde4, treatment of adult patients with oral ulcers associated with behcet's disease using a dosage titration schedule, treatment of psoriatic arthritis with apremilast using a dosage titration schedule and a second active agent, treatment of patients with plaque psoriasis who are candidates for phototherapy or systemic therapy, use of otezla (apremilast) for the treatment of psoriatic arthritis.
Drug patent challenges can be filed against Otezla from 21 March, 2018.
The generics of Otezla are possible to be released after 29 May, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-248) | Jul 19, 2026 |
| New Indication(I-884) | Dec 20, 2024 |
| M(M-299) | Jul 20, 2026 |
| New Chemical Entity Exclusivity(NCE) | Mar 21, 2019 |
| New Indication(I-694) | Sep 23, 2017 |
| New Indication(I-803) | Jul 19, 2022 |
| M(M-257) | Apr 10, 2023 |
Drugs and Companies using APREMILAST ingredient
NCE-1 date: 21 March, 2018
Market Authorisation Date: 21 March, 2014
Treatment: Use of otezla (apremilast) for the treatment of psoriatic arthritis; Treatment of patients with plaque psoriasis who are candidates for phototherapy or systemic therapy; Use of otezla (apremilast) for...
Dosage: TABLET;ORAL
OTEZLA family patents
